Provigil ADHD Application Likely To Be Reviewed By New Neurological Division
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon expects continuity of review for Provigil's additional indication despite FDA's reorganization. The company has three upcoming filings that could be affected by the proposed split of the neuropharm division.
You may also be interested in...
Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up
FDA received eight applications in December, down from 17 in the last month of 2003. However, 2004 marked a return to the agency’s historical flood of year-end approvals.
Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up
FDA received eight applications in December, down from 17 in the last month of 2003. However, 2004 marked a return to the agency’s historical flood of year-end approvals.
FDA Reorganization Of New Drug Office Would Split Neuropharmaceutical Division
Neurology and psychiatry drugs would be reviewed in separate divisions under the proposed restructuring. The reorganization, which aims to group products by therapeutic indications and integrate the review of biologics and drugs, would eliminate ODE V.